Jennifer Tousignant Sells 2,272 Shares of Viridian Therapeutics (NASDAQ:VRDN) Stock

Viridian Therapeutics, Inc. (NASDAQ:VRDN) insider Jennifer Tousignant sold 2,272 shares of Viridian Therapeutics stock in a transaction that occurred on Wednesday, December 31st. The shares were sold at an average price of $31.16, for a total transaction of $70,795.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Viridian Therapeutics Stock Down 1.4%

VRDN stock opened at $30.68 on Friday. Viridian Therapeutics, Inc. has a one year low of $9.90 and a one year high of $34.04. The company has a debt-to-equity ratio of 0.07, a quick ratio of 11.28 and a current ratio of 11.28. The firm’s fifty day moving average is $29.73 and its 200 day moving average is $22.40. The firm has a market cap of $2.93 billion, a PE ratio of -10.16 and a beta of 0.90.

Viridian Therapeutics (NASDAQ:VRDN) last posted its earnings results on Wednesday, November 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.48. Viridian Therapeutics had a negative net margin of 426.58% and a negative return on equity of 78.50%. The business had revenue of $70.57 million for the quarter, compared to analyst estimates of $16.21 million. The firm’s revenue was up 81993.0% on a year-over-year basis. On average, research analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Wall Street Analyst Weigh In

VRDN has been the subject of several research analyst reports. Needham & Company LLC upped their target price on Viridian Therapeutics from $34.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, December 23rd. Wedbush boosted their price target on shares of Viridian Therapeutics from $42.00 to $47.00 and gave the stock an “outperform” rating in a report on Wednesday, December 10th. Oppenheimer increased their price objective on shares of Viridian Therapeutics from $32.00 to $36.00 and gave the company an “outperform” rating in a report on Tuesday, October 21st. BTIG Research reiterated a “buy” rating and issued a $61.00 target price on shares of Viridian Therapeutics in a research report on Tuesday, November 4th. Finally, Truist Financial set a $41.00 price target on shares of Viridian Therapeutics in a research report on Monday, November 24th. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Viridian Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $41.75.

Institutional Investors Weigh In On Viridian Therapeutics

A number of large investors have recently modified their holdings of the business. Aster Capital Management DIFC Ltd acquired a new stake in shares of Viridian Therapeutics in the third quarter valued at about $35,000. Farther Finance Advisors LLC raised its holdings in Viridian Therapeutics by 332.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,940 shares of the company’s stock valued at $42,000 after acquiring an additional 1,491 shares during the last quarter. Bessemer Group Inc. lifted its stake in Viridian Therapeutics by 947.7% in the 3rd quarter. Bessemer Group Inc. now owns 2,085 shares of the company’s stock worth $45,000 after purchasing an additional 1,886 shares in the last quarter. Larson Financial Group LLC acquired a new position in shares of Viridian Therapeutics during the 3rd quarter worth approximately $52,000. Finally, US Bancorp DE grew its position in shares of Viridian Therapeutics by 23.2% in the third quarter. US Bancorp DE now owns 2,457 shares of the company’s stock valued at $53,000 after purchasing an additional 463 shares in the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.